• Clustermarket

  Participated · Seed · Apr 2017

  Clustermarket operates an online platform that allows life-science experts, companies and institutions to share technology and infrastructure and to offer whole scientific services. The company is London-based and led by CEO Johannes Solzbach. In April 2017 Clustermarket closed a £250k seed funding round. It intends to use the funds to grow its business by establishing itself in the "Golden Triangle" (Cambridge, London and Oxford), expand its platform within the UK, and develop complementary features on the platform. The platform’s core product is the marketplace for sharing lab technology and infrastructure and for offering scientific services. The article does not report operating metrics or additional financing details.

• Jellagen

  Led · Equity · Apr 2016

  Jellagen develops Collagen Type 0, a jellyfish-derived collagen biomaterial sourced from Rhizostoma pulmo for use in medical devices and culture applications. The jellyfish-derived material is intended to avoid disease and virus-transfer risks associated with mammalian collagens. The company plans to accelerate medical development of Collagen Type 0 and advance its program toward human trials and regulatory filing. Jellagen has established development collaborations with research organisations including the Mayo Clinic in the US and partners in Europe to investigate and corroborate its findings. The company is led by CEO Thomas‑Paul Descamps and bases its work on research from Professor Andrew Mearns Spragg. Jellagen is based in Cardiff, Wales, UK, and recently closed an £8.7M Series A to support its clinical and regulatory programs. Jellagen develops advanced collagen biomaterials sourced from a single species of jellyfish, which the company says avoids mammalian disease risks and offers superior healing benefits. The company has an established range of products for the cell culture reagent market and has completed pre-clinical datasets in proven animal models supporting use in human tissue reconstruction, diabetic wound healing and other medical applications. Jellagen has conducted collaborations with leading research organisations in the US and Europe and notes recent data have been published in peer-reviewed scientific articles. The company plans to develop and partner pipeline products aimed at tissue reconstruction, diabetic wound care management and rare skin applications. Jellagen intends to explore development and licensing arrangements with potential pharma and medical-device partners to commercialize its findings. The business was founded in 2015 and is based in Cardiff, Wales. Jellagen is a commercial manufacturer of jellyfish collagen based in Cardiff, Wales. Its jellyfish collagen is intended for wound care and regenerative medicine, and the company's first product range comprises cell culture reagents used to grow stem cells. Jellagen also plans to produce medical devices engineered around jellyfish collagen. Founded in 2013 by Professor Andrew Mearns Spragg (CEO), the firm is advancing commercial applications of its collagen. The company received funding to accelerate sales of its jellyfish-based medicine, grow its specialist management team and strengthen its intellectual property portfolio. Jellagen exploits jellyfish to provide next‑generation collagen biomaterials for application in 3D cell culture, in vitro diagnostics (including research‑level regenerative medicine R&D) and medical devices. The company completed a further £1.53m in equity funding to support its operations and growth. Jellagen intends to use the funds to expand and increase its collagen processing capacity and to establish a Quality Management System. It plans to recruit up to six new staff over the next two years and to strengthen and build its IP portfolio. The company will also allocate capital to business development and marketing activities aimed at increasing sales. Jellagen was founded in August 2013 by Dr Andrew Mearns Spragg and is based in Pembroke Dock, UK.

• Desktop Genetics

  Participated · Equity · Sep 2015

  Desktop Genetics develops the DESKGEN genome‑editing software platform, providing lab‑validated CRISPR design algorithms that walk users through the full gene‑editing workflow. The platform aggregates the latest advances and expertise so researchers can design reagents, purchase DNA and access external service providers without their own specialist labs. DTG reports the DESKGEN platform has enabled over 2,000 gene‑editing experiments and attracted thousands of users. The company partners with service providers and industry players including Transcriptic, Horizon Discovery, Editas Medicine and enEvolv to offer library design, synthesis and high‑throughput screening services. Recent funding will be used to continue development and commercialization of DESKGEN with a particular focus on integration with next‑generation sequencing pipelines. DTG is also investing the new capital in expanding its sales infrastructure and marketing to drive broader adoption of the technology. Desktop Genetics develops software to support genome-editing workflows, enabling scientists to design, build and test the DNA molecules needed to translate genomic information into medical innovation. Its DESKGEN product allows users to design any genome-editing experiment in any cell line and to generate tailored CRISPR library designs for research. The company raised £1.4m in funding and plans to use the proceeds to continue developing its platform and to expand operations. Leadership named in the article includes Riley Doyla (CEO), Victor Dillard (CFO) and Edward Perello (CBO). The company is based in London, UK.

• StepJockey

  Participated · Equity · Sep 2015

  StepJockey combines near-field technologies and behavioural economics to promote wellness in multi-storey office buildings by labelling stairs for calorie burn and gamifying stair use by staff. Launched in November 2013 by CEO Paul Nuki and based in London, the company has labelled more than 6,000 staircases in 90 countries. Its customer roster includes Deloitte, Disney, Barclays, KPMG, ITV, Jones Lang LaSalle, Lloyds of London and Legal & General, as well as hospitals, universities and public authorities. The business was seed-funded by the UK Department of Health via the Small Business Research Initiative (SBRI). StepJockey intends to use the newly raised funds to expand sales, marketing and product development operations.

No current team members are available.